Annatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells

A temporal sequential study

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Annatto-derived tocotrienol (AnTT) has been shown to improve bone formation in animal models of osteoporosis. However, detailed studies of the effects of AnTT on preosteoblastic cells were limited. This study was conducted to investigate the osteogenic effect of AnTT on preosteoblast MC3T3-E1 cells in a time-dependent manner. Materials and methods: Murine MC3T3-E1 preosteoblastic cells were cultured in the different concentrations of AnTT (0.001–1 µg/mL) up to 24 days. Expression of osteoblastic differentiation markers was measured by qPCR (osterix [OSX], collagen 1 alpha 1 [COL1α1], alkaline phosphatase [ALP], and osteocalcin [OCN]) and by fluorometric assay for ALP activity. Detection of collagen and mineralized nodules was done via Direct Red staining and Alizarin Red staining, respectively. Results: The results showed that osteoblastic differentiation-related genes, such as OSX, COL1α1, ALP, and OCN, were significantly increased in the AnTT-treated groups compared to the vehicle group in a time-dependent manner (P<0.05). Type 1 collagen level was increased from day 3 to day 15 in the AnTT-treated groups, while ALP activity was increased from day 9 to day 21 in the AnTT-treated groups (P<0.05). Enhanced mineralization was observed in the AnTT-treated groups via increasing Alizarin Red staining from day 3 to day 21 (P<0.05). Conclusion: Our results suggest that AnTT enhances the osteogenic activity by promoting the bone formation-related genes and proteins in a temporal and sequential manner.

Original languageEnglish
Pages (from-to)1715-1726
Number of pages12
JournalDrug Design, Development and Therapy
Volume12
DOIs
Publication statusPublished - 13 Jun 2018

Fingerprint

Tocotrienols
Alkaline Phosphatase
Collagen
Osteocalcin
Staining and Labeling
Osteogenesis
annatto
Differentiation Antigens
Collagen Type I
Osteoporosis
Cultured Cells
Animal Models

Keywords

  • Bone
  • Differentiation
  • Osteoporosis
  • Tocotrienol
  • Vitamin E

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{9eeca3b59be0446b930c0eb54ef4b1f2,
title = "Annatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells: A temporal sequential study",
abstract = "Purpose: Annatto-derived tocotrienol (AnTT) has been shown to improve bone formation in animal models of osteoporosis. However, detailed studies of the effects of AnTT on preosteoblastic cells were limited. This study was conducted to investigate the osteogenic effect of AnTT on preosteoblast MC3T3-E1 cells in a time-dependent manner. Materials and methods: Murine MC3T3-E1 preosteoblastic cells were cultured in the different concentrations of AnTT (0.001–1 µg/mL) up to 24 days. Expression of osteoblastic differentiation markers was measured by qPCR (osterix [OSX], collagen 1 alpha 1 [COL1α1], alkaline phosphatase [ALP], and osteocalcin [OCN]) and by fluorometric assay for ALP activity. Detection of collagen and mineralized nodules was done via Direct Red staining and Alizarin Red staining, respectively. Results: The results showed that osteoblastic differentiation-related genes, such as OSX, COL1α1, ALP, and OCN, were significantly increased in the AnTT-treated groups compared to the vehicle group in a time-dependent manner (P<0.05). Type 1 collagen level was increased from day 3 to day 15 in the AnTT-treated groups, while ALP activity was increased from day 9 to day 21 in the AnTT-treated groups (P<0.05). Enhanced mineralization was observed in the AnTT-treated groups via increasing Alizarin Red staining from day 3 to day 21 (P<0.05). Conclusion: Our results suggest that AnTT enhances the osteogenic activity by promoting the bone formation-related genes and proteins in a temporal and sequential manner.",
keywords = "Bone, Differentiation, Osteoporosis, Tocotrienol, Vitamin E",
author = "{Wan Hasan}, {Wan Nuraini} and {Abd. Ghafar}, Norzana and {Kok Yong}, Chin and Soelaiman, {Ima Nirwana}",
year = "2018",
month = "6",
day = "13",
doi = "10.2147/DDDT.S168935",
language = "English",
volume = "12",
pages = "1715--1726",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Annatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells

T2 - A temporal sequential study

AU - Wan Hasan, Wan Nuraini

AU - Abd. Ghafar, Norzana

AU - Kok Yong, Chin

AU - Soelaiman, Ima Nirwana

PY - 2018/6/13

Y1 - 2018/6/13

N2 - Purpose: Annatto-derived tocotrienol (AnTT) has been shown to improve bone formation in animal models of osteoporosis. However, detailed studies of the effects of AnTT on preosteoblastic cells were limited. This study was conducted to investigate the osteogenic effect of AnTT on preosteoblast MC3T3-E1 cells in a time-dependent manner. Materials and methods: Murine MC3T3-E1 preosteoblastic cells were cultured in the different concentrations of AnTT (0.001–1 µg/mL) up to 24 days. Expression of osteoblastic differentiation markers was measured by qPCR (osterix [OSX], collagen 1 alpha 1 [COL1α1], alkaline phosphatase [ALP], and osteocalcin [OCN]) and by fluorometric assay for ALP activity. Detection of collagen and mineralized nodules was done via Direct Red staining and Alizarin Red staining, respectively. Results: The results showed that osteoblastic differentiation-related genes, such as OSX, COL1α1, ALP, and OCN, were significantly increased in the AnTT-treated groups compared to the vehicle group in a time-dependent manner (P<0.05). Type 1 collagen level was increased from day 3 to day 15 in the AnTT-treated groups, while ALP activity was increased from day 9 to day 21 in the AnTT-treated groups (P<0.05). Enhanced mineralization was observed in the AnTT-treated groups via increasing Alizarin Red staining from day 3 to day 21 (P<0.05). Conclusion: Our results suggest that AnTT enhances the osteogenic activity by promoting the bone formation-related genes and proteins in a temporal and sequential manner.

AB - Purpose: Annatto-derived tocotrienol (AnTT) has been shown to improve bone formation in animal models of osteoporosis. However, detailed studies of the effects of AnTT on preosteoblastic cells were limited. This study was conducted to investigate the osteogenic effect of AnTT on preosteoblast MC3T3-E1 cells in a time-dependent manner. Materials and methods: Murine MC3T3-E1 preosteoblastic cells were cultured in the different concentrations of AnTT (0.001–1 µg/mL) up to 24 days. Expression of osteoblastic differentiation markers was measured by qPCR (osterix [OSX], collagen 1 alpha 1 [COL1α1], alkaline phosphatase [ALP], and osteocalcin [OCN]) and by fluorometric assay for ALP activity. Detection of collagen and mineralized nodules was done via Direct Red staining and Alizarin Red staining, respectively. Results: The results showed that osteoblastic differentiation-related genes, such as OSX, COL1α1, ALP, and OCN, were significantly increased in the AnTT-treated groups compared to the vehicle group in a time-dependent manner (P<0.05). Type 1 collagen level was increased from day 3 to day 15 in the AnTT-treated groups, while ALP activity was increased from day 9 to day 21 in the AnTT-treated groups (P<0.05). Enhanced mineralization was observed in the AnTT-treated groups via increasing Alizarin Red staining from day 3 to day 21 (P<0.05). Conclusion: Our results suggest that AnTT enhances the osteogenic activity by promoting the bone formation-related genes and proteins in a temporal and sequential manner.

KW - Bone

KW - Differentiation

KW - Osteoporosis

KW - Tocotrienol

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=85048693978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048693978&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S168935

DO - 10.2147/DDDT.S168935

M3 - Article

VL - 12

SP - 1715

EP - 1726

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -